AG˹ٷ

STOCK TITAN

Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Waters Corporation (NYSE:WAT) reported strong Q2 2025 financial results, with sales reaching $771 million, representing a 9% increase as reported and 8% in constant currency. The company achieved GAAP EPS of $2.47 and non-GAAP EPS of $2.95, exceeding guidance expectations.

Key performance highlights include mid-single-digit instrument growth led by LC and MS segments, and an 11% constant currency growth in recurring revenue. Pharma segment grew 11%, Industrial increased 6%, while Academic & Government declined 3%. Based on strong performance, Waters raised its full-year 2025 guidance, projecting constant currency sales growth of 5.5% to 7.5% and non-GAAP EPS of $12.95 to $13.05.

Waters Corporation (NYSE:WAT) ha riportato solidi risultati finanziari per il secondo trimestre del 2025, con vendite pari a 771 milioni di dollari, registrando un aumento del 9% a valori correnti e dell'8% a valuta costante. L'azienda ha ottenuto un EPS GAAP di 2,47 dollari e un EPS non-GAAP di 2,95 dollari, superando le aspettative di guidance.

I principali punti di forza includono una crescita a una cifra media degli strumenti guidata dai segmenti LC e MS, e un incremento dell'11% a valuta costante dei ricavi ricorrenti. Il segmento Pharma è cresciuto dell'11%, l'Industriale del 6%, mentre il settore Accademico e Governativo ha registrato un calo del 3%. Grazie a queste solide performance, Waters ha rivisto al rialzo la guidance per l'intero 2025, prevedendo una crescita delle vendite a valuta costante compresa tra il 5,5% e il 7,5% e un EPS non-GAAP tra 12,95 e 13,05 dollari.

Waters Corporation (NYSE:WAT) reportó sólidos resultados financieros en el segundo trimestre de 2025, con ventas que alcanzaron los 771 millones de dólares, representando un aumento del 9% reportado y del 8% en moneda constante. La compañía logró un EPS GAAP de 2.47 dólares y un EPS no-GAAP de 2.95 dólares, superando las expectativas de la guía.

Los aspectos destacados del desempeño incluyen un crecimiento de un dígito medio en instrumentos liderado por los segmentos LC y MS, y un crecimiento del 11% en moneda constante en ingresos recurrentes. El segmento farmacéutico creció un 11%, el industrial aumentó un 6%, mientras que el académico y gubernamental disminuyó un 3%. Basándose en este sólido desempeño, Waters elevó su guía para todo el año 2025, proyectando un crecimiento de ventas en moneda constante del 5.5% al 7.5% y un EPS no-GAAP de 12.95 a 13.05 dólares.

Waters Corporation (NYSE:WAT)� 2025� 2분기 강력� 재무 실적� 발표했으�, 매출은 7� 7,100� 달러� 보고 기준 9%, 환율 변동을 제외� 실질 기준 8% 증가했습니다. 회사� GAAP 주당순이�(EPS) 2.47달러비GAAP EPS 2.95달러� 기록하며 가이던� 기대치를 초과 달성했습니다.

주요 성과로는 LC � MS 부문이 주도� 중간 � 자릿� 기기 성장� 환율 변동을 제외� 11%� 반복 매출 증가가 포함됩니�. 제약 부문은 11%, 산업 부문은 6% 성장했으�, 학계 � 정부 부문은 3% 감소했습니다. 강력� 실적� 바탕으로 Waters� 2025� 연간 가이던스를 상향 조정하여 환율 변동을 제외� 매출 성장률을 5.5%에서 7.5%�, 비GAAP EPS� 12.95에서 13.05달러� 전망했습니다.

Waters Corporation (NYSE:WAT) a annoncé de solides résultats financiers pour le deuxième trimestre 2025, avec des ventes atteignant 771 millions de dollars, soit une augmentation de 9 % en données publiées et de 8 % en devise constante. La société a réalisé un BPA GAAP de 2,47 $ et un BPA non-GAAP de 2,95 $, dépassant les attentes des prévisions.

Les points forts incluent une croissance à un chiffre moyen des instruments, portée par les segments LC et MS, ainsi qu'une croissance de 11 % en devise constante des revenus récurrents. Le segment pharmaceutique a progressé de 11 %, l'industriel de 6 %, tandis que le secteur académique et gouvernemental a diminué de 3 %. Fort de ces performances solides, Waters a relevé ses prévisions pour l'ensemble de l'année 2025, anticipant une croissance des ventes en devise constante comprise entre 5,5 % et 7,5 % et un BPA non-GAAP compris entre 12,95 et 13,05 $.

Waters Corporation (NYSE:WAT) meldete starke Finanzergebnisse für das zweite Quartal 2025, mit einem Umsatz von 771 Millionen US-Dollar, was einem Anstieg von 9 % in Berichtsform und 8 % in konstanter Währung entspricht. Das Unternehmen erzielte ein GAAP-Gewinn je Aktie (EPS) von 2,47 US-Dollar und ein non-GAAP EPS von 2,95 US-Dollar und übertraf damit die Prognosen.

Zu den wichtigsten Leistungshöhepunkten zählen ein mittleres einstelliger Wachstum bei Instrumenten, angeführt von den LC- und MS-Segmenten, sowie ein Wachstum der wiederkehrenden Umsätze um 11 % in konstanter Währung. Das Pharmasegment wuchs um 11 %, der Industriesektor um 6 %, während der akademische und staatliche Bereich um 3 % zurückging. Aufgrund der starken Leistung hat Waters seine Prognose für das Gesamtjahr 2025 angehoben und erwartet ein Umsatzwachstum in konstanter Währung von 5,5 % bis 7,5 % sowie ein non-GAAP EPS von 12,95 bis 13,05 US-Dollar.

Positive
  • None.
Negative
  • Academic & Government segment declined 3%

Insights

Waters delivered strong Q2 results with 8% constant currency growth, raising guidance amid robust pharma demand and instrument replacement cycles.

Waters Corporation's Q2 2025 results demonstrate exceptional execution with sales of $771 million, exceeding their guidance range and growing 9% as reported (8% in constant currency) year-over-year. Their non-GAAP EPS of $2.95 grew an impressive 12% from $2.63 in the year-ago quarter, also beating guidance expectations.

The company's performance was driven by multiple growth engines working in tandem. The instrument segment posted mid-single-digit growth in constant currency, with liquid chromatography (LC) and mass spectrometry (MS) segments leading with high-single-digit growth. This reflects a healthy capital expenditure environment, particularly among large pharmaceutical companies and contract development and manufacturing organizations (CDMOs) that are replacing aging equipment.

Recurring revenue streams, which provide stability and visibility to future performance, grew even faster at 11% in constant currency. This includes 9% growth in services and double-digit growth in chemistry products, indicating strong utilization of Waters' installed instrument base.

By end market, pharmaceutical sales grew 11% in constant currency, showing robust demand in Waters' core customer base. Industrial applications grew 6%, while Academic & Government declined 3% but performed better than management had anticipated. The company highlighted multiple growth vectors including GLP-1 therapeutics (weight loss/diabetes drugs), PFAS testing (forever chemicals), and generic pharmaceuticals.

Management's increased confidence is evident in their raised full-year 2025 guidance, now projecting constant currency sales growth of 5.5% to 7.5% (up from previous guidance) and non-GAAP EPS of $12.95 to $13.05. This represents year-over-year EPS growth of 9% to 10% (10% to 11% in constant currency).

Waters is also advancing its growth strategy through its combination with BD Biosciences & Diagnostic Solutions, which expands its reach into high-growth adjacencies and resilient, high-volume end markets. The integration will be led by Chris Ross, who previously worked with CEO Dr. Udit Batra on the EMD Millipore–Sigma-Aldrich integration, suggesting management has experience executing complex business combinations.

Highlights

  • Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency
  • GAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range
  • Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth � with continued strength in instrument replacement, particularly among large pharma and CDMO customers
  • Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth
  • In constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expected
  • Raising full-year 2025 constant currency sales growth guidance to +5.5% to +7.5% and raising full-year 2025 non-GAAP EPS guidance to $12.95 to $13.05

Second Quarter 2025

MILFORD, Mass., Aug. 4, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT),today announced its financial results for the second quarter of 2025.

Sales for the second quarter of 2025 were $771 million, an increase of 9% as reported and 8% in constant currency, compared to sales of $709 million for the second quarter of 2024.

On a GAAP basis, diluted earnings per share (EPS) for the second quarter of 2025 was $2.47, compared to $2.40 for the second quarter of 2024. Non-GAAP EPS for the second quarter of 2025 grew 12% to $2.95, compared to $2.63 for the second quarter of 2024.

"Our team continues to execute extremely well and we delivered excellent results again this quarter, driven by robust instrument replacement trends–particularly among large pharma and CDMO customers," said Dr. Udit Batra, President & CEO, Waters Corporation. "Our performance reflects strong execution against our commercial growth initiatives, rapid uptake of our new products, and contribution from incremental growth vectors such as GLP-1s,PFAS and generics. As a result, we are raising our full-year sales and earnings guidance."

Dr. Batra continued, "The strength of our core business provides the foundation for our next phase of growth. Our combination with BD Biosciences & Diagnostic Solutions accelerates our strategy into multiple high-growth adjacencies, while extending the reach of our proven execution model into resilient, high-volume end markets. We are well positioned to drive substantial value creation for shareholders with synergies that create immediate impact. Integration planning is underway, and I'm pleased to share that Chris Ross,SVP of Global Operations, will lead this effort. Chris and I successfully partnered on the EMD Millipore–Sigma-Aldrich integration, and I'm confident in his leadership to deliver strong results once again."

A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website in the Investor Relations section.

Full-Year and Third Quarter 2025 Financial Guidance

Full-Year 2025 Financial Guidance

The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +5.5% to +7.5%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +5.0% to +7.0%.

The Company is raising its full-year 2025 non-GAAP EPS guidance to the range of $12.95 to $13.05. This reflects year-over-year growth of approximately +9% to +10%, and +10% to +11% on a constant currency basis.

Third Quarter 2025 Financial Guidance

The Company expects third quarter 2025 constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, third quarter 2025 reported sales growth is expected in the range of +4.5% to +6.5%.

The Company expects thirdquarter 2025 non-GAAP EPS to be in the range of $3.15 to $3.25, which reflects year-over-year growth of approximately +8% to +11%.

Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year and thirdquarter.

Conference Call Details

Waters Corporation will webcast its second quarter 2025 financial results conference call today, August 4, 2025, at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit , select "Investor Relations" under the "About Waters" section, navigate to "Events & Presentations," and click on the "Webcast." A replay will be available through at least September 2, 2025.

About Waters Corporation

Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

Additional Information and Where to Find It

This release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. It does not constitute a prospectus or prospectus equivalent document. No offering or sale of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"), and otherwise in accordance with applicable law.

In connection with the proposed transaction between Waters, Augusta SpinCo Corporation ("SpinCo") and Becton, Dickinson and Company ("BD"), the parties intend to file relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including, among other filings, a registration statement on Form S-4 to be filed by Waters (the "Form S-4") that will include a preliminary proxy statement/prospectus of Waters and a definitive proxy statement/prospectus of Waters, the latter of which will be mailed to stockholders of Waters, and a registration statement on Form 10 to be filed by SpinCo that will incorporate by reference certain portions of the Form S-4 and will serve as an information statement/prospectus in connection with the spin-off of SpinCo from BD. INVESTORS AND SECURITY HOLDERS OF WATERS AND BD ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, THE INFORMATION STATEMENT/PROSPECTUS AND ANY OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders will be able to obtain free copies of the Form S-4 and the proxy statement/prospectus (when available) and other documents filed with the SEC by Waters, SpinCo or BD through the website maintained by the SEC at . Copies of the documents filed with the SEC by Waters will be available free of charge on Waters' website at waters.com under the tab "About Waters" and under the heading "Investor Relations" and subheading "Financials—SEC Filings." Copies of the documents filed with the SEC by BD and SpinCo will be available free of charge on BD's website at bd.com under the tab "About BD" and under the heading "Investors" and subheading "SEC Filings."

Participants in the Solicitation

Waters and BD and their respective directors and executive officers may be considered participants in the solicitation of proxies from Waters' stockholders in connection with the proposed transaction. Information about the directors and executive officers of Waters is set forth in its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 25, 2025, and its proxy statement for its 2025 annual meeting, which was filed with the SEC on April 9, 2025. To the extent holdings of Waters' securities by its directors or executive officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Information about the directors and executive officers of Waters and other information regarding the potential participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction. Information about the directors and executive officers of BD is set forth in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed with the SEC on November 27, 2024, and its proxy statement for its 2025 annual meeting, which was filed with the SEC on December 19, 2024. To the extent holdings of BD's securities by its directors or executive officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at and from Waters' website and BD's website as described above.

Non-GAAP Financial Measures

This release contains financial measures, such as constant currency growth rates, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Definitions of the non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Our actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks or uncertainties related to expectations regarding our strategy, our future financial and operational performance, future economic and market conditions, including our expectations about the growth rates of certain markets, our strategic initiatives, including our instrument replacement initiatives, respond and adapt to changing global dynamics, including the potential impacts of tariffs and supply chain challenges, our ability to retain and attract customers in various geographies and market segments, our market size and growth opportunities, our competitive positioning, projected costs, technological capabilities and plans, and objectives of management. Furthermore, important factors related to the proposed transaction between Waters, BD and SpinCo could cause actual results to differ materially from those currently anticipated, including that one or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived, on a timely basis or otherwise, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction, may require conditions, limitations or restrictions in connection with such approvals or that the required approval by the stockholders of Waters may not be obtained, the risk that the proposed transaction may not be completed on the terms or in the time frame expected by Waters, or at all, unexpected costs, charges or expenses resulting from the proposed transaction, uncertainty of the expected financial performance of the combined company following completion of the proposed transaction, failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all, the ability of the combined company to implement its business strategy, difficulties and delays in the combined company achieving revenue and cost synergies, inability of the combined company to retain and hire key personnel, the occurrence of any event that could give rise to termination of the proposed transaction, the risk that stockholder litigation in connection with the proposed transaction or other litigation, settlements or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability, evolving legal, regulatory and tax regimes, changes in general economic and/or industry specific conditions or any volatility resulting from the imposition of and changing policies around tariffs, actions by third parties, including government agencies, the risk that the anticipated tax treatment of the proposed transaction is not obtained, the risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD, risks related to the disruption of management time from ongoing business operations due to the pendency of the proposed transaction, or other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties; and other risk factors detailed from time to time in Waters' reports filed with the SEC. Such factors and others are discussed more fully in the sections entitled "Forward-Looking Statements" and "Risk Factors" of the Company's annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission ("SEC"), which discussions are incorporated by reference in this release, as updated by the Company's future filings with the SEC. The forward-looking statements included in this release represent the Company's estimates or views as of the date of this release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

Waters Corporation and Subsidiaries

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)















Three Months Ended


Six Months Ended


June 28, 2025


June 29, 2024


June 28, 2025


June 29, 2024








Net sales

$ 771,332


$ 708,529


$ 1,433,037


$ 1,345,368









Costs and operating expenses:








Cost of sales

321,407


288,244


598,152


550,030

Selling and administrative expenses

201,257


173,247


376,138


347,783

Research and development expenses

48,548


46,182


95,170


90,777

Purchased intangibles amortization

11,907


11,744


23,619


23,578

Litigation provision

-


-


-


10,242








Operating income

188,213


189,112


339,958


322,958








Other (expense) income, net

(676)


(302)


848


1,957

Interest expense, net

(9,847)


(19,398)


(20,228)


(40,647)








Income from operations before income taxes

177,690


169,412


320,578


284,268








Provision for income taxes

30,579


26,675


52,086


39,335








Net income

$ 147,111


$ 142,737


$ 268,492


$ 244,933
















Net income per basic common share

$ 2.47


$ 2.41


$ 4.51


$ 4.13








Weighted-average number of basic common shares

59,515


59,339


59,478


59,287
















Net income per diluted common share

$ 2.47


$ 2.40


$ 4.50


$ 4.12








Weighted-average number of diluted common shares and equivalents

59,656


59,451


59,686


59,445









Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segments, Products & Services, Geography and Markets

Three Months Ended June 28, 2025 and June 29, 2024

(In thousands)
































Constant






Three Months Ended


Percent


Impact of


Currency






June 28, 2025


June 29, 2024


Change


Currency


Growth Rate (a)
















NET SALES - OPERATING SEGMENTS





























Waters



$

688,837


$

622,561


11%


1%


10%

TA





82,495



85,968


(4%)


2%


(6%)
















Total




$

771,332


$

708,529


9%


1%


8%
































NET SALES - PRODUCTS & SERVICES




























Instruments



$

308,415


$

294,059


5%


1%


4%
















Service




297,932



273,385


9%


0%


9%

Chemistry




164,985



141,085


17%


1%


16%

Total Recurring




462,917



414,470


12%


1%


11%
















Total




$

771,332


$

708,529


9%


1%


8%
































NET SALES - GEOGRAPHY




























Asia




$

265,940


$

237,431


12%


(2%)


14%

Americas




280,740



274,468


2%


0%


2%

Europe




224,652



196,630


14%


6%


8%
















Total




$

771,332


$

708,529


9%


1%


8%
































NET SALES - MARKETS




























Pharmaceutical



$

461,968


$

415,747


11%


1%


11%

Industrial




237,655



221,385


7%


1%


6%

Academic & Government



71,709



71,397


0%


3%


(3%)
















Total




$

771,332


$

708,529


9%


1%


8%

















































(a)


The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.


















Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segments, Products & Services, Geography and Markets

Six Months Ended June 28, 2025 and June 29, 2024

(In thousands)

































Constant







Six Months Ended


Percent


Impact of


Currency







June 28, 2025


June 29, 2024


Change


Currency


Growth Rate (a)


















NET SALES - OPERATING SEGMENTS






























Waters



$

1,276,134


$

1,184,460


8%


(1%)


9%


TA





156,903



160,908


(2%)


1%


(3%)


















Total




$

1,433,037


$

1,345,368


7%


(1%)


7%



































NET SALES - PRODUCTS & SERVICES






























Instruments



$

571,308


$

536,003


7%


(1%)


7%


















Service




559,107



534,073


5%


(1%)


6%


Chemistry




302,622



275,292


10%


0%


10%


Total Recurring




861,729



809,365


6%


(1%)


8%


















Total




$

1,433,037


$

1,345,368


7%


(1%)


7%



































NET SALES - GEOGRAPHY






























Asia




$

486,716


$

444,990


9%


(4%)


13%


Americas




536,277



515,639


4%


0%


4%


Europe




410,044



384,739


7%


2%


5%


















Total




$

1,433,037


$

1,345,368


7%


(1%)


7%



































NET SALES - MARKETS






























Pharmaceutical



$

853,019


$

789,954


8%


(1%)


9%


Industrial




441,020



416,719


6%


0%


6%


Academic & Government



138,998



138,695


0%


0%


0%


















Total




$

1,433,037


$

1,345,368


7%


(1%)


7%





















































(a)


The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.































Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP Financials

Three and Six Months Ended June 28, 2025 and June 29, 2024

(In thousands, except per share data)


















































Income from






























Operations















Selling &



Research &






Operating



Other



before



Provision for






Diluted






Administrative



Development



Operating



Income



(Expense)



Income



Income



Net



Earnings






Expenses(a)



Expenses



Income



Percentage



Income



Taxes



Taxes



Income



per Share

Three Months Ended June 28, 2025




























GAAP



$

213,164


$

48,548


$

188,213



24.4%


$

(676)


$

177,690


$

30,579


$

147,111


$

2.47

Adjustments:






























Purchased intangibles amortization (b)



(11,907)



-



11,907



1.5%



-



11,907



2,820



9,087



0.15


Restructuring costs and certain other items (c)



(3,869)



-



3,869



0.5%



-



3,869



912



2,957



0.05


ERP implementation and transformation costs (d)



(5,082)



-



5,082



0.7%



-



5,082



1,220



3,862



0.06


Acquisition related costs (e)



(14,284)



-



14,284



1.9%



-



14,284



2,391



11,893



0.20


Retention bonus obligation (g)



(955)



(318)



1,273



0.2%



-



1,273



305



968



0.02

Adjusted Non-GAAP


$

177,067


$

48,230


$

224,628



29.1%


$

(676)


$

214,105


$

38,227


$

175,878


$

2.95






























Three Months Ended June 29, 2024




























GAAP



$

184,991


$

46,182


$

189,112



26.7%


$

(302)


$

169,412


$

26,675


$

142,737


$

2.40

Adjustments:






























Purchased intangibles amortization (b)



(11,744)



-



11,744



1.7%



-



11,744



2,810



8,934



0.15


Restructuring costs and certain other items (c)



(1,139)



-



1,139



0.2%



-



1,139



280



859



0.01


Retention bonus obligation (g)



(3,817)



(1,272)



5,089



0.7%



-



5,089



1,221



3,868



0.07

Adjusted Non-GAAP


$

168,291


$

44,910


$

207,084



29.2%


$

(302)


$

187,384


$

30,986


$

156,398


$

2.63






























Six Months Ended June 28, 2025




























GAAP



$

399,757


$

95,170


$

339,958



23.7%


$

848


$

320,578


$

52,086


$

268,492


$

4.50

Adjustments:






























Purchased intangibles amortization (b)



(23,619)



-



23,619



1.6%



-



23,619



5,652



17,967



0.30


Restructuring costs and certain other items (c)



(4,467)



-



4,467



0.3%



-



4,467



1,056



3,411



0.06


ERP implementation and transformation costs (d)



(7,377)



-



7,377



0.5%



-



7,377



1,771



5,606



0.09


Acquisition related costs (e)



(14,284)



-



14,284



1.0%



-



14,284



2,391



11,893



0.20


Retention bonus obligation (g)



(2,864)



(954)



3,818



0.3%



-



3,818



916



2,902



0.05

Adjusted Non-GAAP


$

347,146


$

94,216


$

393,523



27.5%


$

848


$

374,143


$

63,872


$

310,271


$

5.20






























Six Months Ended June 29, 2024




























GAAP



$

381,603


$

90,777


$

322,958



24.0%


$

1,957


$

284,268


$

39,335


$

244,933


$

4.12

Adjustments:






























Purchased intangibles amortization (b)



(23,578)



-



23,578



1.8%



-



23,578



5,642



17,936



0.30


Restructuring costs and certain other items (c)



(9,486)



-



9,486



0.7%



-



9,486



2,335



7,151



0.12


Litigation provision and settlement (f)



(10,242)



-



10,242



0.8%



-



10,242



2,458



7,784



0.13


Retention bonus obligation (g)



(9,542)



(3,181)



12,723



0.9%



-



12,723



3,053



9,670



0.16

Adjusted Non-GAAP


$

328,755


$

87,596


$

378,987



28.2%


$

1,957


$

340,297


$

52,823


$

287,474


$

4.84








































(a)

Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements.

(b)

The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

(c)

Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

(d)

ERP implementation and transformation costs represent costs related to the Company's initiative to transition from its legacy enterprise resource planning (ERP) system to a new global ERP solution with a cloud-based infrastructure. These costs, which do not represent normal or future ongoing business expenses, are one-time, non-recurring costs related to the establishment of our new global ERP solution that were determined to be non-capitalizable in accordance with accounting standards.

(e)

Acquisition related costs include all incremental costs incurred to effect the business combination, such as advisory, legal, accounting, tax, valuation, and other professional fees. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

(f)

Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly.

(g)

In connection with the Wyatt acquisition, the Company recognized a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

Waters Corporation and Subsidiaries

Preliminary Condensed Unclassified Consolidated Balance Sheets

(In thousands and unaudited)





























June 28, 2025


December 31, 2024








Cash and cash equivalents



$ 367,215


$ 325,355

Accounts receivable




730,074


733,365

Inventories




540,754


477,261

Property, plant and equipment, net


645,267


651,200

Intangible assets, net




579,127


567,906

Goodwill





1,337,908


1,295,720

Other assets




517,730


502,988

Total assets




$ 4,718,075


$ 4,553,795
















Notes payable and debt



$ 1,456,966


$ 1,626,488

Other liabilities




1,101,297


1,098,800

Total liabilities




2,558,263


2,725,288









Total stockholders' equity



2,159,812


1,828,507

Total liabilities and stockholders' equity


$ 4,718,075


$ 4,553,795

Waters Corporation and Subsidiaries

Preliminary Condensed Consolidated Statements of Cash Flows

Three and Six Months Ended June 28, 2025 and June 29, 2024

(In thousands and unaudited)
















Three Months Ended



Six Months Ended





June 28, 2025


June 29, 2024



June 28, 2025


June 29, 2024








Cash flows from operating activities:










Net income

$ 147,111


$ 142,737



$ 268,492


$ 244,933


Adjustments to reconcile net income to net












cash provided by operating activities:











Stock-based compensation

13,097


11,433



25,975


22,346



Depreciation and amortization

51,649


47,229



101,018


95,743



Change in operating assets and liabilities and other, net

(170,716)


(146,865)



(94,791)


(45,618)




Net cash provided by operating activities

41,141


54,534



300,694


317,404












Cash flows from investing activities:










Additions to property, plant, equipment












and software capitalization

(22,594)


(36,104)



(48,336)


(64,759)


Business acquisitions, net of cash acquired

(34,969)


-



(34,969)


-


Investments in unaffiliated companies

(789)


-



(1,295)


(1,064)


Net change in investments

-


(11)



-


(36)




Net cash used in investing activities

(58,352)


(36,115)



(84,600)


(65,859)












Cash flows from financing activities:










Net change in debt

(4,506)


(50,000)



(174,506)


(350,000)


Proceeds from stock plans

4,492


7,904



12,738


21,836


Purchases of treasury shares

(375)


(245)



(14,309)


(13,334)


Other cash flow from financing activities, net

(639)


8,304



1,802


15,285




Net cash used in financing activities

(1,028)


(34,037)



(174,275)


(326,213)












Effect of exchange rate changes on cash and cash equivalents

2,582


4,755



41


6,019




(Decrease) increase in cash and cash equivalents

(15,657)


(10,863)



41,860


(68,649)













Cash and cash equivalents at beginning of period

382,872


337,290



325,355


395,076




Cash and cash equivalents at end of period

$ 367,215


$ 326,427



$ 367,215


$ 326,427
















‌�





















Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)





































Net cash provided by operating activities - GAAP

$ 41,141


$ 54,534



$ 300,694


$ 317,404













Adjustments:











Additions to property, plant, equipment












and software capitalization

(22,594)


(36,104)



(48,336)


(64,759)



Tax reform payments

120,006


95,645



120,006


95,645



Litigation settlements paid, net

-


9,625



-


9,250



Payment of Wyatt retention bonus obligation (b)

20,127


19,770



20,127


19,770

Free Cash Flow - Adjusted Non-GAAP

$ 158,680


$ 143,470



$ 392,491


$ 377,310













(a)

The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.













(b)

During the six months ended June 28, 2025 and June 29, 2024, the Company made retention payments under the Wyatt retention bonus program. The Company believes that these payments are not normal and do not represent future ongoing business expenses.












Waters Corporation and Subsidiaries

Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook

























Twelve Months Ended


Three Months Ended





December 31, 2025


September 27, 2025






Range




Range



Projected Sales



















Constant currency sales growth rate (a)

5.5%

-

7.5%


5.0%

-

7.0%


Currency translation impact

(0.5%)

-

(0.5%)


(0.5%)

-

(0.5%)


Sales growth rate as reported

5.0%

-

7.0%


4.5%

-

6.5%



























Range




Range



Projected Earnings Per Diluted Share




















GAAP earnings per diluted share

$ 11.45

-

$ 11.55


$ 2.70

-

$ 2.80


Adjustments:











Purchased intangibles amortization

$ 0.60

-

$ 0.60


$ 0.15

-

$ 0.15



Restructuring costs and certain other items

$ 0.07

-

$ 0.07


$ 0.01

-

$ 0.01



ERP implementation and transformation costs

$ 0.25

-

$ 0.25


$ 0.08

-

$ 0.08



Acquisition related costs

$ 0.53

-

$ 0.53


$ 0.21

-

$ 0.21



Retention bonus obligation

$ 0.05

-

$ 0.05


$ -

-

$ -


Adjusted non-GAAP earnings per diluted share

$ 12.95

-

$ 13.05


$ 3.15

-

$ 3.25













(a) Constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results.













These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.




Contact: Caspar Tudor, Head of Investor Relations � (508) 482-3448

Cision View original content:

SOURCE Waters Corporation

FAQ

What were Waters Corporation's (WAT) Q2 2025 earnings results?

Waters reported Q2 2025 sales of $771 million, up 9% as reported, with GAAP EPS of $2.47 and non-GAAP EPS of $2.95.

What is Waters Corporation's (WAT) full-year 2025 guidance?

Waters raised its full-year 2025 guidance, expecting constant currency sales growth of 5.5% to 7.5% and non-GAAP EPS of $12.95 to $13.05.

How did Waters' (WAT) different business segments perform in Q2 2025?

Pharma segment grew 11%, Industrial grew 6%, while Academic & Government declined 3% in constant currency.

What is Waters Corporation's (WAT) Q3 2025 financial outlook?

Waters expects Q3 2025 constant currency sales growth of 5.0% to 7.0% and non-GAAP EPS between $3.15 to $3.25.

How did Waters' (WAT) recurring revenue perform in Q2 2025?

Recurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growth.
Waters

NYSE:WAT

WAT Rankings

WAT Latest News

WAT Latest SEC Filings

WAT Stock Data

17.80B
59.41M
0.16%
98.23%
3.39%
Diagnostics & Research
Laboratory Analytical Instruments
United States
MILFORD